Cancer is a strong focus of epigenetic research. A critical issue in oncology is that average cancer treatment isn’t producing the best outcomes for the majority of people. Drug companies trying to produce effective treatments for the average of the population, struggle with poor results in large scale clinical trials. Patients are clamoring for personalized medicine. To meet this goal, clinicians need cancer biomarkers. Through excellent research efforts, epigenomics is adding a richer temporal dimension into our view of oncogenesis. Epigenetic regulation mechanisms act as a group of musicians playing from the composition of the genetic code. They play as a large orchestra of integrated gene networks, keeping cells on a differentiated path. Researchers have identified three main sections in … Continue reading →